Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF.

N Engl J Med. 2007 Jan 18;356(3):217-26.

2.

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H.

Clin Cancer Res. 2005 Feb 1;11(3):1154-9.

3.

A gene-expression signature as a predictor of survival in breast cancer.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R.

N Engl J Med. 2002 Dec 19;347(25):1999-2009.

4.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.

5.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
6.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.

Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22.

PMID:
20094918
7.

The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.

Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L.

Hum Pathol. 2008 Jul;39(7):1096-102. doi: 10.1016/j.humpath.2007.12.003. Epub 2008 May 20.

PMID:
18495204
8.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.

Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26.

PMID:
18819002
9.

Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.

Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C.

Neoplasia. 2009 Oct;11(10):987-1002.

10.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
11.

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.

Breast Cancer Res. 2006;8(5):R59.

12.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27.

PMID:
18661261
13.

A six-gene signature predicting breast cancer lung metastasis.

Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretière JM, Ricevuto E, Noguès C, Briffod M, Bièche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, Driouch K.

Cancer Res. 2008 Aug 1;68(15):6092-9. doi: 10.1158/0008-5472.CAN-08-0436.

14.

Population-based molecular prognosis of breast cancer by transcriptional profiling.

Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.

Clin Cancer Res. 2007 Apr 1;13(7):2014-22.

15.

Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.

Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.

Oncology. 2011;81(5-6):336-44. doi: 10.1159/000334690. Epub 2012 Jan 11.

PMID:
22237177
16.

Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.

Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.

Clin Cancer Res. 2008 Nov 15;14(22):7452-60. doi: 10.1158/1078-0432.CCR-08-1077.

17.

Prediction of breast cancer prognosis by gene expression profile of TP53 status.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C.

Cancer Sci. 2008 Feb;99(2):324-32. doi: 10.1111/j.1349-7006.2007.00691.x.

18.

[Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].

Lu ZQ, Li HG, Zhang HZ, Fan MJ, Shen XM, He XX.

Ai Zheng. 2008 Jun;27(6):575-9. Chinese.

PMID:
18570728
19.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

20.

Supplemental Content

Support Center